ArticleMolecules (Basel, Switzerland)2025
De Novo Design of Large Polypeptides Using a Lightweight Diffusion Model Integrating LSTM and Attention Mechanism Under Per-Residue Secondary Structure Constraints.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SegDesign: A modular framework for controllable protein segment engineering.Protein science : a publication of the Protein Society · 2026Article
- AI-driven biomaterial design: an intelligent closed loop from reverse design to biological response.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study presents PolypeptideDesigner (PPD), a novel conditional diffusion-based model for de novo polypeptide sequence design and generation based on per-residue secondary structure conditions. By integrating a lightweight LSTM-attention neural network as the denoiser within a diffusion framework, PPD offers an innovative and efficient approach to polypeptide generation. Evaluations demonstrate that the PPD model can generate diverse and novel polypeptide sequences across various testing conditions, achieving high pLDDT scores when folded by ESMFold. In comparison to the ProteinDiffusionGenerator B (PDG-B) model, a relevant benchmark in the field, PPD exhibits the ability to produce longer and more diverse polypeptide sequences. This improvement is attributed to PPD's optimized architecture and expanded training dataset, which enhance its understanding of protein structural pattern. The PPD model shows significant potential for optimizing functional polypeptides with known structures, paving the way for advancements in biomaterial design. Future work will focus on further refining the model and exploring its broader applications in polypeptide engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.